Clinical validation of a novel high-sensitivity cardiac troponin i assay for early diagnosis of acute myocardial infarction

127Citations
Citations of this article
141Readers
Mendeley users who have this article in their library.
Get full text

Abstract

BACKGROUND: Clinical performance of the novel highsensitivity cardiac troponin I (Siemens-hs-cTnI-Centaur) assay is unknown. We aimed to clinically validate the Siemens-hs-cTnI-Centaur assay and develop 0/1-h and 0/2-h algorithms. METHODS: We enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by 2 independent cardiologists including all clinical information twice: first, using serial hscTnT (Roche-Elecsys, primary analysis); second, using hs-cTnI (Abbott-Architect, secondary analysis) measurements in addition to the clinically applied (hs)-cTn. Siemens-hs-cTnI-Centaur was measured at presentation, 1 h, and 2 h. The primary objective was a direct comparison of diagnostic accuracy, quantified by the area under the ROC curve (AUC), of Siemens-hs-cTnI-Centaur vs the 2 established hs-cTn assays (Roche-hs-cTnT-Elecsys, Abbott-hs-cTnI-Architect). Secondary objectives included the development of Siemens-hs-cTnI-Centaur-specific 0/1-h and 0/2-h algorithms. RESULTS: AMI was the final diagnosis in 318 of 1755 (18%) patients (using Roche-hs-cTnT-Elecsys for adjudication). The AUC at presentation for Siemens-hs-cTnICentaur was 0.94 (95% CI, 0.92- 0.96) and comparable with 0.95 (95% CI, 0.93- 0.97) for Roche-hs-cTnTElecsys and 0.93 (95% CI, 0.90-0.96) for Abbott-hscTnI-Architect. Applying the derived Siemens-hs-cTnICentaur 0/1-h algorithm to the validation cohort, 46% of patients were ruled out (sensitivity, 99.1%; 95% CI, 95.3-100), and 18% of patients were ruled in (specificity, 94.1%; 95% CI, 91.8 -95.9). The Siemens-hs-cTnICentaur 0/2-h algorithm ruled out 55% of patients (sensitivity, 100%; 95% CI, 94.1-100), and ruled in 18% of patients (specificity, 96.0%; 95% CI, 93.1-97.9). Findings were confirmed in the secondary analyses using serial measurements of Abbott-hs-cTnI-Architect for adjudication. CONCLUSIONS: Diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur assay are high and comparable with the established hs-cTn assays.

Cite

CITATION STYLE

APA

Boeddinghaus, J., Twerenbold, R., Nestelberger, T., Badertscher, P., Wildi, K., Puelacher, C., … Parenica, J. (2018). Clinical validation of a novel high-sensitivity cardiac troponin i assay for early diagnosis of acute myocardial infarction. Clinical Chemistry, 64(9), 1347–1360. https://doi.org/10.1373/clinchem.2018.286906

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free